Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL7525505 | 0.92 | TSHR (0.51) | TSHRTGM2MEN1KMT2AL3MBTL1 | |
| SCHEMBL7252186 | 0.90 | TSHR (0.69) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12745804 | 0.84 | TSHR (0.60) | TSHRTGM2MEN1KMT2AL3MBTL1 | |
| SCHEMBL3598006 | 0.82 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL10117993 | 0.82 | TSHR (0.61) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3598004 | 0.82 | TSHR (0.61) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL81094 | 0.82 | FPR3 (0.58) | TGM2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL2021427 | 0.81 | FPR2 (0.58) | MEN1KMT2AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL3006709 | 0.81 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2721206 | 0.81 | ALDH1A1 (0.65) | TSHRMEN1KMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2010005841-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | TSHR 1389/4885TGM2 2260/4885MEN1 1115/4885 |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | TSHR 4037/4885TGM2 934/4885MEN1 2831/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | TSHR 4037/4885TGM2 934/4885MEN1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.